Etelcalcetide to protect vitamin K activity in dialysis patients.
Part of Hormones & metabolism, Injuries & trauma clinical trials.
This study tests a medicine called etelcalcetide to see if it can protect vitamin K activity in people with kidney disease and overactive parathyroid glands who are on dialysis. It aims to slow down calcium buildup in blood vessels and reduce heart valve problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You are on hemodialysis (a type of kidney treatment) three times a week.
- Your parathyroid hormone (PTH) level is above 500 pg/ml in two recent blood tests.
- You have calcium buildup in your blood vessels or heart valves, as seen on imaging.
- You have not taken certain bone or calcium medicines (like bisphosphonates, denosumab, or teriparatide) in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different types of dialysis fluid affect calcium buildup in the blood vessels of people with kidney disease on hemodialysis. It may help improve heart health for dialysis patients.
This study tests whether taking a very high dose of vitamin D3 can reduce moderate to severe chronic pain in people on hemodialysis. It may help by improving vitamin D-related pathways that could affect pain, but you must also meet specific health and testing requirements.
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
This Phase 3 trial tests etelcalcetide to lower a hormone called parathyroid hormone (PTH) in children who have kidney disease and secondary hyperparathyroidism while on hemodialysis. It may help control bone/mineral problems, but the study also checks heart rhythm safety and medication stability.
This trial compares two vitamin D medicines (doxercalciferol and calcitriol) to see which better controls high parathyroid hormone levels in people on dialysis. If you join, you'll get one of these medicines to help keep your bones and blood minerals healthy.
This trial tests a new medicine called MT1013 for people with secondary hyperparathyroidism who are on dialysis. It may help control high parathyroid hormone levels when current treatments are not enough.
Hear when a new Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.